Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance

Reactivated androgen receptor (AR) signaling drives castration‐resistant prostate cancer (CRPC). The novel AR targeting drugs abiraterone and enzalutamide have improved survival of CRPC patients. However, resistance to these agents develops and patients ultimately succumb to CRPC. Potential mechanis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology and therapeutics 2015-12, Vol.98 (6), p.582-589
Hauptverfasser:	Crona, DJ, Milowsky, MI, Whang, YE
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen Receptor Antagonists - adverse effects Androgen Receptor Antagonists - therapeutic use Animals Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Drug Resistance, Neoplasm - genetics Humans Ligands Male Molecular Targeted Therapy Neoplasms, Hormone-Dependent - drug therapy Neoplasms, Hormone-Dependent - metabolism Neoplasms, Hormone-Dependent - pathology Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - genetics Prostatic Neoplasms, Castration-Resistant - metabolism Prostatic Neoplasms, Castration-Resistant - pathology Receptors, Androgen - drug effects Receptors, Androgen - genetics Receptors, Androgen - metabolism Signal Transduction - drug effects Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!